Epigenetic fragility of the endocannabinoid system under stress: risk for mood disorders and pharmacogenomic implications

Click to increase image sizeClick to decrease image size

Financial and competing interests disclosure

Research in AW’s lab is partially funded by the Israel Science Foundation, The Israel Ministry of Science and EPM, Inc. Research in TLR’s lab is funded by Grant 1R01HD087509 from the National Institute of Child Health and Human Development. These funding sources did not have any input in the content of this manuscript. Beyond the above, the authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

Research in AW’s lab is partially funded by the Israel Science Foundation, The Israel Ministry of Science and EPM, Inc. Research in TLR’s lab is funded by Grant 1R01HD087509 from the National Institute of Child Health and Human Development. These funding sources did not have any input in the content of this manuscript. Beyond the above, the authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.